News | Breast Density | September 20, 2019

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial

Densityai software will be deployed in up to 24 breast cancer screening clinics across Germany

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial

September 20, 2019 — Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast cancer screening clinics across Germany. These clinics will provide breast density measurements at point of care to identify women for supplemental breast cancer screening as part of the DIMASOS 2 Trial.

Prof. Sylvia H. Heywang-Köbrunner, M.D., head of Referenzzentrum Mammographie München, internationally recognized for her work in contrast-enhanced breast magnetic resonance imaging (MRI) and modern biopsy procedures, is using densitas densityai breast density measures to establish a supplemental ultrasound screening protocol in the DIMASOS 2 trial.

“Women with dense breasts are subject to the masking effect of mammographic density and its association with breast cancer risk. The objective of the DIMASOS 2 trial is to test whether combined mammography/ultrasound exams can improve early cancer detection and if this can feasibly and cost effectively be done in routine screening workflow,” said Heywang-Köbrunner.  “The unique ability of the Densitas software to analyze prior ‘for presentation’ mammograms from a wide range of mammography scanner vendor models is pivotal to this trial and is important for any practical clinical deployment.”

Densitas densityai delivers fully automated, standardized and reproducible breast density assessments from standard DICOM clinical use mammograms. Results from densitas densityai are generated by two distinct algorithms that decouple the breast density assessment into quantitative and qualitative scales in alignment with the American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BI-RADS) 4th and 5th edition density classification systems. These results can be incorporated into breast cancer risk models to provide standardized and reproducible patient-specific risk estimates.

The artificial intelligence (AI)-driven Densitas densityai processes the same clinical use images that radiologists examine, enabling seamless picture archiving and communication system (PACS)-centric integrations and retrospective auditing capabilities of routinely archived exams. 

For more information: www.densitas.health

Related Content

A World Health Organization (WHO) rapid advice guide on the use of chest imaging in the diagnosis and management of COVID-19 was published in the journal Radiology.

Getty Images

News | Coronavirus (COVID-19) | July 30, 2020
July 30, 2020 — A World Health Organization (WHO) rapid advice gui
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...
 The Radiological Society of North America (RSNA) has been awarded a $750,000 grant by the Department of Energy’s National Nuclear Security Administration (NNSA) to develop a Global Learning Center (GLC) in Sub-Saharan Africa. The grant will help address the growing need in Sub-Saharan Africa for training in radiology.
News | Radiology Education | July 28, 2020
July 28, 2020 — The Radiological Society of North America (RSNA)
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine latera

(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine lateral sampling (requiring dithering); the filled circles show the data that are sampled without dithering.

News | Computed Tomography (CT) | July 24, 2020
July 24, 2020 — A computed tomography (CT) sca